Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash & Equivalents (2018 - 2025)

Silence Therapeutics' Cash & Equivalents history spans 8 years, with the latest figure at $11.3 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 90.71% to $11.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.3 million, a 90.71% decrease, with the full-year FY2025 number at $11.3 million, down 90.71% from a year prior.
  • Cash & Equivalents hit $11.3 million in Q4 2025 for Silence Therapeutics, down from $102.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for SLN hit a ceiling of $143.4 million in Q1 2024 and a floor of $11.3 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $84.3 million across 5 years, with a median of $80.0 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: surged 676.88% in 2021 and later crashed 90.71% in 2025.
  • Tracing SLN's Cash & Equivalents over 5 years: stood at $99.1 million in 2021, then crashed by 35.14% to $64.3 million in 2022, then grew by 4.3% to $67.1 million in 2023, then surged by 80.93% to $121.3 million in 2024, then crashed by 90.71% to $11.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for SLN at $11.3 million in Q4 2025, $102.2 million in Q3 2025, and $114.2 million in Q2 2025.